Cargando…
Patient with Down syndrome and relapsed acute lymphoblastic leukemia with sustained remission despite only partial R3 chemotherapy
DS‐ALL has a higher rate of relapse and treatment‐related mortality. The newer immunotherapies are potentially better options. Relapsed ALL with positive MRD has a poor prognosis. Transient long‐term remission after ALL relapse due to partial chemotherapy combined severe infection is rare.
Autores principales: | Hu, Zhongbo, VanHeyst, Kristen A., Dalal, Jignesh, Hackney, Lisa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981660/ https://www.ncbi.nlm.nih.gov/pubmed/33768794 http://dx.doi.org/10.1002/ccr3.3678 |
Ejemplares similares
-
Ectopic Tumor VCAM-1 Expression in Cancer Metastasis and Therapy Resistance
por: VanHeyst, Kristen A., et al.
Publicado: (2022) -
Relapse after Prolonged Remission in Philadelphia-Like Acute Lymphoblastic Leukemia
por: Shah, Gaurav, et al.
Publicado: (2019) -
T-Cell Lymphoblastic Leukemia/Lymphoma: Relapse 16 Years after First Remission
por: Elreda, Lauren, et al.
Publicado: (2014) -
Unilateral optic nerve infiltration as an initial site of relapse of acute lymphoblastic leukemia in remission
por: Bandyopadhyay, Sabyasachi, et al.
Publicado: (2010) -
Successful Treatment of Fanconi Anemia and T-Cell Acute Lymphoblastic Leukemia
por: Flatt, Terrie, et al.
Publicado: (2012)